Parapoxviruses are strongly inhibited in vitro by cidofovir.
Three parapoxviruses which cause orf or related diseases in humans and animals and the orthopoxvirus, vaccinia virus, were tested for their in vitro sensitivity to cidofovir. The 50% inhibitory concentration for the three parapoxviruses was between 0.21 and 0.27 microg/ml and for vaccinia was 1.32 microg/ml. The selectivity index varied from 198 to 264 for the parapoxviruses and was 42 for vaccinia virus. Virus yield assays confirmed the ability of cidofovir to reduce ortho- and parapoxvirus replication. The efficacy of cidofovir against parapoxviruses justifies its evaluation as a candidate drug for the treatment of parapoxvirus infections in humans and animals.
Nettleton
P F
PF
Moredun Research Institute, Pentlands Science Park, Bush Loan, EH26 0PZ, Edinburgh, UK. nettp@mri.sari.ac.uk
Gilray
J A
JA
Reid
H W
HW
Mercer
A A
AA
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives / Q000494:pharmacology*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D018157:Parapoxvirus / Q000187:drug effects* / Q000502:physiology; D011213:Poxviridae Infections / Q000821:virology; D012756:Sheep; D014615:Vaccinia / Q000821:virology; D014616:Vaccinia virus / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir